Phibro Animal Health stock reaches 52-week high at $30.60

Phibro Animal Health (NASDAQ:PAHC) Corporation’s stock has reached a new 52-week high, hitting $30.60. With a market capitalization of $1.23 billion and revenue growth of 19.12%, the company has shown strong momentum. According to InvestingPro analysis, the stock’s RSI indicates overbought conditions, suggesting investors should exercise caution at current levels. This milestone underscores a significant upward trend for the company, which has seen its stock price climb by an impressive 83.77% over the past year. The surge reflects strong investor confidence, supported by a healthy current ratio of 2.91 and consistent profitability. However, with a P/E ratio of 38.78, InvestingPro’s Fair Value analysis suggests the stock may be overvalued at current levels. Phibro’s stock performance over the past year highlights its resilience and growth potential in the competitive animal health sector. Discover 12 additional exclusive ProTips and comprehensive research reports for PAHC on InvestingPro.

In other recent news, Phibro Animal Health Corporation reported strong financial results for the third quarter of 2025, surpassing both earnings and revenue expectations. The company achieved an adjusted diluted EPS of $0.63, exceeding the projected $0.53, and reported revenue of $347.8 million, above the anticipated $309.5 million. This marks a 32% year-over-year increase in revenue, with the Animal Health segment leading with a 42% rise in sales. The integration of the Zoetis (NYSE:ZTS) medicated feed additives (MFA) business significantly contributed to this growth, generating higher margins than expected. In light of these results, JPMorgan upgraded Phibro’s stock rating to Overweight from Neutral, raising the price target to $35.00 from $25.00, citing strong execution and favorable industry fundamentals. JPMorgan’s fiscal 2026 estimates for Phibro now stand above consensus expectations. Despite the stock’s strong performance this year, analysts at JPMorgan see further upside potential due to Phibro’s attractive valuation. The company also provided an optimistic outlook for the full year 2025, projecting net sales between $1.260 billion and $1.290 billion, representing a 24-27% increase, and expects adjusted EBITDA to grow by 59-66%.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.